

# 東邦大学学術リポジトリ

Toho University Academic Repository

タイトル	Analyses of N methyl D aspartate receptor related metabolites in the serum of antipsychotic naïve individuals with at risk mental state
別タイトル	抗精神病薬未服薬の発症危険状態におけるN methyl D aspartate 受容体関連代謝物の解析
作成者（著者）	田形, 弘実
公開者	東邦大学
発行日	2020.03.15
掲載情報	東邦大学大学院医学研究科 博士論文.
資料種別	学位論文
内容記述	主査：桂川修一 / タイトル：Analyses of N methyl D aspartate receptor related metabolites in the serum of antipsychotic naïve individuals with at risk mental state / 著者：Hiromi Tagata, Naohisa Tsujino, Mayu Onozato, Takahiro Nemoto, Takeshi Fukushima, Masafumi Mizuno / 掲載誌：Toho Journal of Medicine / 巻号・発行年等：6(2):90-97, 2020 / 本文ファイル：出版者版
著者版フラグ	ETD
報告番号	32661甲第947号
学位記番号	甲第652号
学位授与年月日	2020.03.15
学位授与機関	東邦大学
その他資源識別子	<a href="https://mylibrary.toho-u.ac.jp/webopac/TD39126483">https://mylibrary.toho-u.ac.jp/webopac/TD39126483</a>
その他資源識別子	<a href="https://doi.org/10.14994/tohojmed.2019_026">info:doi/10.14994/tohojmed.2019_026</a>
メタデータのURL	<a href="https://mylibrary.toho-u.ac.jp/webopac/TD37018029">https://mylibrary.toho-u.ac.jp/webopac/TD37018029</a>

# Analyses of *N*-Methyl-D-Aspartate Receptor-Related Metabolites in the Serum of Antipsychotic-Naïve Individuals with at-Risk Mental State

Hiromi Tagata<sup>1)\*</sup> Naohisa Tsujino<sup>1,2)</sup> Mayu Onozato<sup>3)</sup>  
Takahiro Nemoto<sup>1)</sup> Takeshi Fukushima<sup>3)</sup> and Masafumi Mizuno<sup>1)</sup>

<sup>1)</sup>Department of Neuropsychiatry, Toho University Graduate School of Medicine, Tokyo, Japan

<sup>2)</sup>Department of Psychiatry, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan

<sup>3)</sup>Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan

---

## ABSTRACT

**Introduction:** The criteria for “at-risk mental state” have been advocated as a preventive approach to psychosis treatment although their pathophysiological mechanisms remain unclear. Reliable biomarkers to predict transitions from at-risk mental state to psychosis are urgently needed. Since abnormalities in *N*-methyl-D-aspartate receptor co-agonists have been reported in the serum of patients with schizophrenia, several of these metabolite levels in individuals with at-risk mental state were investigated and these levels with clinical symptoms were correlated.

**Methods:** Serum levels of glutamate, cysteine, glycine,  $\gamma$ -glutamylcysteine, glutathione, *D*-serine, and *L*-serine were investigated in antipsychotic-naïve individuals with attenuated psychotic symptoms ( $n = 28$ ) and compared with those in antipsychotic-naïve individuals with first-episode psychosis ( $n = 13$ ) and those in healthy controls ( $n = 41$ ). The serum metabolite levels were measured using high-performance liquid chromatography with fluorescence detection or liquid chromatography with tandem mass spectrometry. Correlations between clinical symptoms and serum metabolite levels in individuals with at-risk mental state were also examined.

**Results:** The glutathione and *D*-serine levels were significantly lower, whereas glutamate levels were significantly higher in individuals with attenuated psychotic symptoms than in healthy controls. Additionally, glutathione levels were significantly decreased in individuals with first-episode psychosis compared with those in healthy controls. In individuals with attenuated psychotic symptoms, clinical scores were not correlated with serum levels of metabolites related to the *N*-methyl-D-aspartate receptor.

**Conclusions:** The results of this study suggest that abnormally altered levels of metabolites related to the *N*-methyl-D-aspartate receptor can already occur in individuals with attenuated psychotic symptoms.

Toho J Med 6 (2): 90–97, 2020

---

**KEYWORDS:** *N*-methyl-D-aspartate receptor, at-risk mental state, attenuated psychotic symptom, schizophrenia, serum biomarker

---

\*Corresponding Author: Hiromi Tagata, 5-21-6, Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan, tel: +81-3-3762-4151  
e-mail: hiromi.tagata@med.toho-u.ac.jp  
DOI: 10.14994/tohojmed.2019-026

Received Oct. 29, 2019; Accepted Nov. 30, 2019  
Toho Journal of Medicine 6 (2), June 1, 2020.  
ISSN 2189-1990, CODEN: TJMOA2

## Introduction

Schizophrenia is one of the severe and chronic mental disorders and can have a deteriorating course. To improve its prognosis, it is important to minimize the duration of untreated psychosis, which is significantly associated with quality of life, social functioning, and cognitive function.<sup>1)</sup> Furthermore, early detection of high-risk state for psychosis for subsequent intervention prevents the transition to psychosis and improves the prognosis after psychosis onset. The at-risk mental state (ARMS) has been advocated as the preventive approach to psychosis treatment.<sup>2)</sup> Although a meta-analysis indicates that ARMS is associated with higher psychosis transition rates,<sup>3)</sup> not all of the affected individuals necessarily convert to psychosis. To date, it is difficult to predict individuals with ARMS who will transition to psychosis relying only on symptom features. Therefore, establishing reliable biomarkers in individuals with ARMS is urgently needed. To identify reliable biomarkers, it is necessary to examine molecules based on the pathophysiology of schizophrenia.

Although the etiology of schizophrenia has not been fully elucidated yet, some convincing hypotheses have been suggested. Among others, *N*-methyl-D-aspartate (NMDA) dysfunction, also termed the “glutamate hypothesis,” has been proposed because NMDA hypofunction causes negative symptoms and cognitive impairment, as well as positive symptoms, in animal and human experiments.<sup>4)</sup> Ketamine and phencyclidine, which are NMDA antagonists, induce schizophrenic-like symptoms in healthy humans.<sup>4)</sup> The NMDA receptor is an ionotropic glutamate receptor, which is activated by binding its agonist glutamic acid (Glu), whereas glycine (Gly) or *D*-serine can bind as co-agonists to the regulatory site of the subunit.<sup>5-7)</sup> In the early 1990s, additional modulatory effects on NMDA receptors by the tripeptide glutathione (GSH) have been described.<sup>8)</sup> Besides, GSH is regarded as one of the endogenous antioxidants and is implicated in the “oxidative stress hypothesis” that has been advocated as the etiology of schizophrenia.<sup>9)</sup> GSH is synthesized from Glu, cysteine (Cys), and Gly.<sup>10)</sup> First,  $\gamma$ -glutamylcysteine ( $\gamma$ -GluCys) is synthesized from glutamate and cysteine. In a second step, glycine is added to  $\gamma$ -GluCys to synthesize GSH. Glutamate metabolites are also agonist or co-agonist of the NMDA receptor and intimately related to the NMDA receptor.

Several studies indicated that serum levels of  $\gamma$ -GluCys,

GSH, and *D*-serine are lower and those of Glu are higher in patients with schizophrenia compared with healthy controls,<sup>11, 12)</sup> whereas another study detected decreased Gly levels in patients with schizophrenia.<sup>13)</sup> Previous studies examining the relationships between blood levels of metabolites related to the NMDA receptor in patients with schizophrenia and their symptoms reported that GSH serum levels were negatively correlated with the total Positive and Negative Syndrome Scale (PANSS)<sup>14, 15)</sup> score of these patients<sup>16)</sup> and plasma *D*-serine levels were correlated with the improvement of their positive symptoms.<sup>17)</sup> However, an analysis of the metabolites related to the NMDA receptor in the serum of individuals with ARMS has not been reported yet. To investigate alterations of biological metabolites in these individuals, we determined serum levels of metabolites related to the NMDA receptor including Glu, Cys, Gly,  $\gamma$ -GluCys, GSH, *D*-serine, and *L*-serine in antipsychotic-naïve individuals with ARMS and compared these levels with those in antipsychotic-naïve individuals with first-episode psychosis (FEP) and in healthy controls. Furthermore, we also correlated the serum levels of these NMDA receptor-related metabolites with the clinical symptoms in individuals with ARMS.

## Materials and Methods

### Participants

This is a cross-sectional observational study of individuals with attenuated psychotic symptoms (APS,  $n = 28$ , those with FEP,  $n = 13$ ), and healthy controls ( $n = 41$ ). All participants were enrolled between June 1, 2014, and December 31, 2018, and individuals with APS or FEP were recruited from the Toho University Omori Medical Center in Tokyo. To minimize the heterogeneity present in ARMS, which could affect the data, we extracted individuals with APS among the ARMS population of this center. All individuals with APS and FEP were help-seeking patients who had already been affected by psychotic symptoms. Individuals with APS satisfied the following criteria: A) participants fulfilled the APS criteria of the Structured Interview for Psychosis-Risk Syndromes/Scale of Psychosis-Risk Symptoms (SIPS/SOPS).<sup>18)</sup> We used the Japanese version of SIPS/SOPS, which we previously demonstrated to have excellent interrater reliability.<sup>19)</sup> The SIPS/SOPS were administered by trained psychiatrists; B) they were 15-40 years old; C) they were native Japanese speakers; and D) they were able to obtain written informed consent. The exclusion criteria for individu-

als with APS were as follows: E) they took antipsychotic medication during the study period or had taken antipsychotics in the past 6 months; and they had F) severe learning disorder, G) organic brain disorder, H) medical history of psychosis, I) severe suicidal thoughts, J) alcohol and drug abuse, K) IQ below 70, and L) comorbidity or medical history of hepatic, renal, or endocrine diseases including diabetes.

Individuals with FEP who experienced the first onset of psychotic symptoms were identified by trained psychiatrists using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-I).<sup>20,21)</sup> The enrolled participants satisfied the criteria B) to D) and all exclusion criteria E) to L).

Additionally, we recruited healthy participants. Healthy controls satisfied the following inclusion criteria: A) they had no history of any mental disorder according to the SCID-I Non-Patient Edition<sup>21,22)</sup> with B) to D) as described above. The exclusion criteria for healthy controls were from E) to L) as mentioned above.

We assessed the clinical symptoms and social functions of study participants with APS. The clinical symptoms were assessed using the PANSS, Beck Depression Inventory second edition (BDI-II),<sup>23)</sup> Clinical Global Impression (CGI),<sup>24)</sup> and the modified Global Assessment of Functioning (GAF) scale.<sup>25,26)</sup> Social functions were assessed by the World Health Organization Quality of Life 26 (WHO-QOL 26),<sup>27,28)</sup> and the Schizophrenia Cognition Rating Scale (SCoRS).<sup>29)</sup> We used the SCoRS Interviewer's Global Rating as a parameter.<sup>30)</sup> Moreover, we determined the duration of untreated illness, which was defined as the interval between the onset of the prodrome and the administration of the first treatment.<sup>31)</sup>

The study protocol was approved by the Ethical Research Committee of the Toho University School of Medicine (A17039-26012). All participants provided written informed consent, or if participants were under 20 years of age, their parents provided written informed consent with the participants giving written assent.

#### Blood sampling and metabolite analysis

Blood samples (10 mL) were collected from an antecubital vein between 8:00 AM and 9:00 AM before breakfast after fasting from 9:00 PM on the previous day to avoid the effects of food intake. The serum was separated by centrifugation and stored at  $-80^{\circ}\text{C}$ . The serum levels of Cys, Gly,  $\gamma$ -GluCys, GSH, Glu, D-serine, and L-serine were measured using high-performance liquid chromatography with

fluorescence detection<sup>32)</sup> or a liquid chromatography with tandem mass spectrometry-based method that we reported before.<sup>33)</sup>

#### Statistical analysis

A one-way analysis of variance (ANOVA) or chi-squared test was employed to analyze group differences in demographic variables. The ANOVA was utilized for the statistical analysis of metabolite concentrations with  $p < 0.05$  considered statistically significant. We used Turkey's HSD test as a post hoc test for multiple comparisons. The Spearman rank correlation test was performed to determine statistical correlations between variables. Statistical analyses were carried out using the Statistical Package for Social Science version 23.0 (IBM, Armonk, NY).

## Results

### Demographics and characteristics of the study participants

The demographics of the participants are presented in Table 1. There were significant group differences in age and sex, whereas the body mass index did not significantly differ among the three study groups. The clinical characteristics of the APS and FEP groups are also shown in Table 1.

### Serum levels of metabolites related to the NMDA receptor in the three study groups

The serum levels of metabolites related to the NMDA receptor are listed in Table 2. The levels of GSH (APS group  $4.3 \pm 1.8 \mu\text{M}$ , healthy controls  $6.4 \pm 2.4 \mu\text{M}$ ;  $p = 0.001$ ) and D-serine (APS group  $0.9 \pm 0.2 \mu\text{M}$ , healthy controls  $1.1 \pm 0.3 \mu\text{M}$ ;  $p = 0.010$ ) were in the APS group significantly lower than in healthy controls. By contrast, the Glu levels (APS group  $184.3 \pm 102.2 \mu\text{M}$ , healthy controls  $131.2 \pm 67.4 \mu\text{M}$ ;  $p = 0.022$ ) were significantly elevated in the APS group compared with the control group. Moreover, the serum levels of GSH (FEP group  $3.8 \pm 2.4 \mu\text{M}$ , healthy controls  $6.4 \pm 2.4 \mu\text{M}$ ;  $p = 0.002$ ) were significantly decreased in the FEP group compared with the healthy controls. The serum levels of the three metabolites that were significantly different among the three groups are shown in Fig. 1.

### Relationships between relative metabolite concentrations and clinical symptoms

Since the serum concentrations of Glu, GSH, and D-serine were significantly different between the APS and control groups, we additionally examined their relationships with demographic characteristics like age, with the clinical

Table 1 Demographic characteristics

Characteristic	Control N = 41	APS N = 28	FEP N = 13	P-value
Age mean (SD), yr	21.6 (2.4)	18.9 (4.9)	28.3 (10.3)	<b>0.000</b> **
Gender				
Female: Male	30:11	10:18	8:5	<b>0.008</b> **
Body Mass Index, mean (SD)	21.7 (4.7)	21.0 (3.0)	20.8 (5.0)	0.69
PANSS		66.9 (15.1)	93.2 (20.8)	-
Positive, mean (SD)	-	15.8 (3.9)	24.4 (4.8)	-
Negative, mean (SD)	-	17.0 (5.4)	24.5 (7.5)	-
General, mean (SD)	-	34.1 (9.1)	45.0 (10.8)	-
BDI-II	-	24.5 (12.3)	19.6 (9.9)	-
CGI, mean (SD)	-	4.6 (0.7)	5.5 (0.8)	-
GAF, mean (SD)	-	46.0 (8.5)	33.9 (12.9)	-
WHOQOL-26, mean (SD)	-	2.7 (0.6)	2.9 (0.4)	-
SCoRS Interviewer's Global Rating (SD)	-	3.9 (1.8)	4.8 (2.2)	-
DUI (SD), M	-	29.2 (61.3)	31.3 (41.8)	-

\*:  $p < 0.05$ , \*\*:  $p < 0.01$

Significant values are highlighted by bold font.

APS, attenuated psychotic symptoms; PANSS, Positive and Negative Syndrome Scale; BDI-II, Beck Depression Inventory-II; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning; WHOQOL-26, World Health Organization Quality of Life-26 Scale; SCoRS, Schizophrenia Cognition Rating Scale; DUI, duration of untreated.

Table 2 Comparison of serum levels of metabolites related to the NMDA receptor among the three groups

	Control N = 41	APS N = 28	FEP N = 13	ANOVA	Post-hoc		
	A	B	C		A vs B	A vs C	B vs C
Glu (SD), $\mu\text{M}$	131.2 (67.4)	184.4 (102.2)	160.4 (59.2)	<b>0.028</b> *	<b>0.022</b> *	0.488	0.647
Cys (SD), $\mu\text{M}$	225.4 (34.8)	237.8 (40.8)	242.3 (34.5)	0.226	0.358	0.929	0.323
$\gamma$ -GluCys (SD), $\mu\text{M}$	4.3 (1.1)	3.7 (1.2)	3.9 (1.1)	0.168	0.161	0.553	0.931
Gly (SD), $\mu\text{M}$	264.7 (57.7)	237.0 (50.0)	243.1 (64.9)	0.119	0.119	0.553	0.945
GSH (SD), $\mu\text{M}$	6.4 (2.4)	4.3 (1.8)	3.8 (2.4)	<b>0.000</b> **	<b>0.001</b> **	<b>0.002</b> **	0.783
D-serine (SD), $\mu\text{M}$	1.1 (0.3)	0.9 (0.2)	1.0 (0.4)	<b>0.012</b> *	<b>0.010</b> *	0.325	0.687
L-serine (SD), $\mu\text{M}$	128.7 (20.0)	124.0 (23.4)	130.2 (48.8)	0.719	0.778	0.764	0.984

\*:  $p < 0.05$ , \*\*:  $p < 0.01$

Significant values are highlighted by bold font.

APS, attenuated psychotic symptoms; FEP, first episode psychosis; Glu, glutamic acid; Cys, cysteine;  $\gamma$ -GluCys,  $\gamma$ -glutamylcysteine; GSH, glutathione; Gly, glycine.

symptoms evaluated by scores in SOPS and its subscales, BDI-II, GAF, CGIC, WHO-QOL26, and SCoRS Interviewer's Global Rating, and with the duration of untreated illness (Table 3). There was no correlation between the metabolite concentrations and the age of the participant. Similarly, we did not detect any relationship between the concentrations of the three examined metabolites Glu, GSH, and D-serine and the clinical symptoms and characteristics.

## Discussion

Regarding the serum analysis of endogenous compounds, we recently reported a significant decrease in serum L-lactate levels in individuals with ARMS.<sup>34)</sup> However, to the best of our knowledge, this is the first investigation that reports serum levels of metabolites related to the NMDA receptor in individuals with ARMS.

The serum levels of GSH in individuals with APS and those with FEP were significantly lower than those in




Fig. 1 Comparison of serum levels of metabolites related to the NMDA receptor among the three study groups. (a) The level of glutamic acid (Glu) in the APS group is significantly higher than that in healthy controls. (b) The glutathione (GSH) levels in the APS and FEP groups are significantly decreased compared with healthy controls. (c) The level of *D*-serine in the APS group is significantly lower than that in healthy controls.

\*:  $p < 0.05$ , \*\*:  $p < 0.01$

Quantitative variables were compared using the one-way analysis of variance (ANOVA).

The y-axis represents the metabolite concentration. Bars indicate mean values.

Table 3 Correlations of serum levels of metabolites related to the NMDA receptor and clinical symptoms in individuals with APS

	Glu	GSH	D-ser
Age	0.034	0.002	-0.04
SOPS total	-0.17	-0.14	-0.19
Positive subscale	0.12	-0.09	-0.01
Negative subscale	-0.20	-0.09	-0.26
Disorganized subscale	-0.22	-0.17	-0.29
General subscale	-0.06	-0.17	-0.16
BDI-II	0.35	-0.32	0.19
GAF	-0.06	-0.04	0.27
CGIC	0.07	-0.16	-0.09
WHO-QOL26	-0.21	0.20	-0.24
SCoRS Interviewer's Global Rating	-0.36	-0.05	-0.26
DUI	-0.11	-0.08	-0.07

There was no correlation between clinical scores and serum levels of metabolites related to the NMDA-receptor in individuals with APS.

SOPS, the Scale of Psychosis-Risk Symptoms Positive and Negative Syndrome Scale; BDI-II, Beck Depression Inventory II; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning; WHO-QOL26, World Health Organization Quality of Life 26; SCoRS, Schizophrenia Cognition Rating Scale; DUI, duration of untreated illness.

healthy controls. Decreased GSH levels in the serum of individuals with schizophrenia have already been reported by several groups.<sup>11,35</sup> Moreover, it has been demonstrated that GSH can bind to and stimulate NMDA receptors.<sup>9</sup> In the view of the glutamate hypothesis, decreased GSH levels may, thus, be related to the NMDA hypofunction.

Therefore, our results suggest that NMDA hypofunction could occur in APS as well as FEP. Although the Glu levels in individuals with APS were increased, there were no significant differences in Glu levels between control and individuals with FEP. We propose that Glu levels in individuals with APS could be increased to compensate for their

NMDA hypofunction in contrast to participants with FEP. This suggests that increased Glu levels may be a crucial factor to distinguish between APS and FEP individuals. However, further longitudinal studies are needed to elucidate the mechanisms of how this alteration in APS causes the transition to schizophrenia.

The D-serine levels were significantly lower in individuals with APS compared with those in healthy controls. Although decreased D-serine levels in the serum or plasma of individuals with schizophrenia have been reported previously by Calcia et al.<sup>36)</sup> and our group,<sup>11)</sup> we detected similarly decreased D-serine levels in individuals with APS. *In vivo*, D-serine is biosynthesized by serine racemase (EC.5.1.1.18) and degraded by D-amino acid oxidase (DAO; EC.1.4.3.3).<sup>37)</sup> Previously, Madeira et al.<sup>38)</sup> reported increased DAO activity in the brain of individuals with schizophrenia. The results of the present study suggest that individuals with APS may exert increased DAO activity.

According to our results in individuals with APS, there was no correlation between their clinical scores and their serum levels of metabolites associated with NMDA receptor activation. We suggest that the reason for the lack of such relationships may be the relative attenuation of symptoms and cognitive dysfunction in APS compared with those in schizophrenia.

In the present study, however, several limitations should be mentioned. First, our sample size was comparatively small, and larger sample sizes are required to confirm the results of the present study. However, these data are valuable. It is also difficult to collect a large number of data from antipsychotic-naïve individuals with APS and FEP. Second, this study examined only serum levels of metabolites. It is possible that the metabolite levels in the peripheral blood samples may not have sufficiently reflected the status of these metabolites in the brain tissue of the study participants. However, some studies reported that the serum levels of some metabolites are correlated with their corresponding cerebral levels.<sup>39)</sup> Third, other potentially confounding factors, such as the menstrual cycle phase, daily food consumption, and drinking, which could have affected the metabolite levels, were not taken into consideration in our analysis because of the lack of this information. Fourth, we should evaluate disease control to confirm specificity. In the next study, we will recruit other mental disorder groups such as depression. Last, there were significant differences in sex among the three study

groups. A previous study found no sex differences in metabolite concentrations.<sup>40)</sup> However, the sample size of this study was comparatively small, and larger studies are required to clarify the influence of sex differences on peripheral metabolite concentrations.

In conclusion, the present study indicated that abnormal levels of metabolites related to the NMDA receptor occurred in individuals with APS. Future longitudinal studies should investigate the relationship between the identified candidate metabolites and the clinical course of individuals with APS who transition to schizophrenia, and multicenter studies are needed to confirm our biomarker results.

**Disclaimer:** Masafumi Mizuno is one of the Editors of Toho Journal of Medicine. He was not involved in the editorial evaluation or decision to accept this article for publication at all.

**Acknowledgements:** The authors thank all participants for providing the blood samples for this study. The authors thank T. Funatogawa, T. Yamaguchi, N. Katagiri for their help to design this study. The authors thank I. Kimura for her analysis of metabolites. The authors thank T. Sakamoto, R. Onuma, S. Furukawa, K. Kobata, A. Uta, and Y. Morita for their technical assistance in the HPLC measurements.

This work was financially supported by the Toho University Joint Research Fund (2015-2016), Inokashira Hospital Grants for Psychiatry Research (2017), and a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C) (grant number 16K08944).

**Conflicts of interest:** None declared.

## References

- 1) Ito S, Nemoto T, Tsujino N, Ohmuro N, Matsumoto K, Matsuoka H, et al. Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. *Eur Psychiatry*. 2015; 30: 995-1001.
- 2) Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull*. 1996; 22: 353-70.
- 3) Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P. Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. *Psychiatry Res*. 2013; 209: 266-72.
- 4) Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. *Hillside J Clin Psychiatry*. 1987; 9: 12-35.
- 5) Mothet JP, Parent AT, Wolosker H, Brady RO Jr., Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine

- site of the N-methyl-D-aspartate receptor. *Proc Natl Acad Sci U S A*. 2000; 97: 4926-31.
- 6) Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, et al. Glycine binding primes NMDA receptor internalization. *Nature*. 2003; 422: 302-7.
  - 7) Pace JR, Martin BM, Paul SM, Rogawski MA. High concentrations of neutral amino acids activate NMDA receptor currents in rat hippocampal neurons. *Neurosci Lett*. 1992; 141: 97-100.
  - 8) Leslie SW, Brown LM, Trent RD, Lee YH, Morris JL, Jones TW, et al. Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione. *Mol Pharmacol*. 1992; 41: 308-14.
  - 9) Bitanirwhe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. *Neurosci Biobehav Rev*. 2011; 35: 878-93.
  - 10) Bachhawat AK, Yadav S. The glutathione cycle: glutathione metabolism beyond the gamma-glutamyl cycle. *IUBMB Life*. 2018; 70: 585-92.
  - 11) Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. *PLoS One*. 2014; 9: e101652.
  - 12) Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, et al. Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. *Clin Neurophysiol*. 2013; 124: 2209-15.
  - 13) Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. *J Proteome Res*. 2011; 10: 5433-43.
  - 14) Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987; 13: 261-76.
  - 15) Igarashi Y, Hayashi N, Yamashina M, Otsuka N, Kuroki N, Anzai N, et al. Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. *Psychiatry Clin Neurosci*. 1998; 52: 467-70.
  - 16) Tsai MC, Liou CW, Lin TK, Lin IM, Huang TL. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. *Psychiatry Res*. 2013; 209: 284-90.
  - 17) Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). *Prog Neuropsychopharmacol Biol Psychiatry*. 2008; 32: 1905-12.
  - 18) Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 2003; 29: 703-15.
  - 19) Kobayashi H, Nozaki S, Mizuno M. (2005). Reliability of the structured interview for prodromal syndromes Japanese version (SIPS-J). *Japanese Bulletin of Social Psychiatry*. 2005; 15: 168-74.
  - 20) First MB, Spitzer RL, Gibbon M, Williams J. Structural clinical interview for DSM-IV axis I disorders (SCID-IV). New York: Biometrics Research Department, New York State Psychiatric Institute; 1997.
  - 21) Takahashi S, Kitamura T, Okano T. Structured clinical interview for DSM-IV-TR axis I disorders. 2nd ed. Tokyo, JP: Nihon Hyoronsha [Article in Japanese]; 2010.
  - 22) First MB, Spitzer RL, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition. (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
  - 23) Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
  - 24) Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration. 1976.
  - 25) Hall RC, Parks J. The modified global assessment of functioning scale: addendum. *Psychosomatics*. 1995; 36: 416-7.
  - 26) Eguchi S, Koike S, Suga M, Takizawa R, Kasai K. Psychological symptom and social functioning subscales of the modified Global Assessment of Functioning scale: reliability and validity of the Japanese version. *Psychiatry Clin Neurosci*. 2015; 69: 126-7.
  - 27) Saxena S, Orley J. Quality of life assessment: the world health organization perspective. *Eur Psychiatry*. 1997; 12: 263s-6s.
  - 28) Kunikata H, Mino Y, Nakajima K. [Factors affecting WHOQOL-26 in community-dwelling patients with schizophrenia]. *Nihon Koshu Eisei Zasshi*. 2006; 53: 301-9. Japanese.
  - 29) Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. *Am J Psychiatry*. 2006; 163: 426-32.
  - 30) Kaneda Y, Ueoka Y, Sumiyoshi T, Yasui-Furukori N, Ito T, Higuchi Y, et al. [Schizophrenia Cognition Rating Scale Japanese version (SCoRS-J) as a co-primary measure assessing cognitive function in schizophrenia]. *Nihon Shinkei Seishin Yakurigaku Zasshi*. 2011; 31: 259-62. Japanese.
  - 31) Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. *Br J Psychiatry*. 2009; 194: 18-24.
  - 32) Kono Y, Iizuka H, Isokawa M, Tsunoda M, Ichiba H, Sadamoto K, et al. HPLC-fluorescence determination of thiol compounds in the serum of human male and female subjects using HILIC-mode column. *Biomed Chromatogr*. 2014; 28: 589-93.
  - 33) Sakamoto T, Kuwabara R, Takahashi S, Onozato M, Ichiba H, Iizuka H, et al. Determination of D-serine in human serum by LC-MS/MS using a triazole-bonded column after pre-column derivatization with (S)-4-(3-isothiocyanatopyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl)-2,1,3-benzoxadiazole. *Anal Bioanal Chem*. 2016; 408: 517-26.
  - 34) Onozato M, Umino M, Shoji A, Ichiba H, Tsujino N, Funatogawa T, et al. Serum d- and l-lactate, pyruvate and glucose levels in individuals with at-risk mental state and correlations with clinical symptoms. *Early Interv Psychiatry*. 2019.
  - 35) Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 33: 1178-83.
  - 36) Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, Vargas-Lopes C, et al. Plasma levels of D-serine in Brazilian individuals with schizophrenia. *Schizophr Res*. 2012; 142: 83-7.
  - 37) Ohide H, Miyoshi Y, Maruyama R, Hamase K, Konno R. D-Amino acid metabolism in mammals: biosynthesis, degradation and analytical aspects of the metabolic study. *J Chromatogr B Analyt*

- Technol Biomed Life Sci. 2011; 879: 3162-8.
- 38) Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. *Schizophr Res.* 2008; 101: 76-83.
- 39) Samuelsson M, Vainikka L, Ollinger K. Glutathione in the blood and cerebrospinal fluid: a study in healthy male volunteers. *Neuropeptides.* 2011; 45: 287-92.
- 40) Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horska A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. *J Magn Reson Imaging.* 2004; 19: 27-33.

©Medical Society of Toho University. Toho Journal of Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).